Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADOBE INC.ADBE · Entity 2895 | Director | June 25, 2026 | June 26, 2026 |
| ELI LILLY & CoLLY · Entity 2794 | Director · President, Chair, and CEO | February 09, 2026 | February 11, 2026 |
| Elanco Animal Health IncELAN · Entity 3457 | Director | September 19, 2018 | September 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADOBE INC.
Report date June 25, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,655 |
Reported balance
After 2026-06-25 transaction · row 1
1 source rowRow 1 · 2026-06-25 · Purchase · Acquired 10,000 · Balance 17,655 F1: This transaction was executed in multiple trades at prices ranging from $194.44 to $194.53. The price reported above reflects the weighted average execution price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Indirectby trust | 2,775 |
Reported balance
Holding disclosure · report date 2026-06-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,775 F2: Shares held by the David A Ricks 12-2022 Grantor Retained Annuity Trust of which the reporting person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $194.44 to $194.53. The price reported above reflects the weighted average execution price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
F2: Shares held by the David A Ricks 12-2022 Grantor Retained Annuity Trust of which the reporting person is a trustee.
ELI LILLY & Co
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 571,715.097 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 38,913.584 · Balance 571,715.097 |
| Common StockSEC Table I · non-derivative | IndirectBy David A. Ricks 2025 GRAT | 6,685 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,685 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy David A. Ricks 2022 GRAT | 54,117 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 54,117 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 300 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 300 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy David A. Ricks SLAT | 68,656 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 68,656 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 7,307.91 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 7,307.91 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Elanco Animal Health Inc
Report date September 19, 2018 · Filed September 19, 2018
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2016 Filed Feb 3, 2016 19:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000308 · wf-form4_145452625935962.xml · derivative · entry 6 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,843 shares Expires 2016-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 19:04 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,273 | $78.36 | $256,472.28 |
DisclosureSEC source: 0000059478-16-000308 · wf-form4_145452625935962.xml · nonDerivative · entry 3 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,863 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2015. F2 · price: This transaction was executed in multiple trades at prices ranging from $78.19 to $78.61. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 19:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,656 | $79.10 | $368,289.60 |
DisclosureSEC source: 0000059478-16-000308 · wf-form4_145452625935962.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,136 Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 19:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000308 · wf-form4_145452625935962.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:52 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000274 · wf-form4_145402513522111.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,244 Underlying: Common Stock · 10,244 shares Expires 2017-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:52 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 19,016 | $81.96 | $1,558,551.36 |
DisclosureSEC source: 0000059478-16-000274 · wf-form4_145402513522111.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,949 Read SEC document |
| December 17, 2015 Filed Jan 25, 2016 20:48 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 72 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000245 · wf-form5_145375492583852.xml · nonDerivative · entry 3 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,933 Read SEC document |
| November 05, 2015 Filed Nov 9, 2015 21:33 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/06 (right to buy) · Derivative | 4,970 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0000059478-15-000184 · wf-form4_144710480852147.xml · derivative · entry 4 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,970 shares Expires 2016-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2015 Filed Nov 9, 2015 21:33 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 3,924 | $81.05 | $318,040.20 |
DisclosureSEC source: 0000059478-15-000184 · wf-form4_144710480852147.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,184 Read SEC document |
| November 05, 2015 Filed Nov 9, 2015 21:33 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 4,970 | $56.18 | $279,214.60 |
DisclosureSEC source: 0000059478-15-000184 · wf-form4_144710480852147.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2015 Filed Nov 16, 2015 20:54 UTC Amendment | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 3,908 | $81.05 | $316,743.40 |
DisclosureSEC source: 0000059478-15-000195 · wf-form4a_144770726103620.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,200 F1 · shares: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| July 23, 2015 Filed Jan 25, 2016 20:48 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 12 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000245 · wf-form5_145375492583852.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,005 Read SEC document |
| March 31, 2015 Filed Jan 25, 2016 20:48 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000245 · wf-form5_145375492583852.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,017 Read SEC document |
| February 04, 2015 Filed Feb 6, 2015 15:06 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,147 | $69.99 | $220,258.53 |
DisclosureSEC source: 0000059478-15-000080 · wf-form4_142323520866384.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,138 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2014. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.80 to $70.25. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2015 Filed Feb 3, 2015 21:08 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 4,769 | $71.51 | $341,031.19 |
DisclosureSEC source: 0000059478-15-000066 · wf-form4_142299772208656.xml · nonDerivative · entry 3 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,285 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2014. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.26 to $71.87. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:08 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000066 · wf-form4_142299772208656.xml · derivative · entry 5 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,591 shares Expires 2015-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:08 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 5,940 | $72.00 | $427,680.00 |
DisclosureSEC source: 0000059478-15-000066 · wf-form4_142299772208656.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,054 Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 21:08 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000066 · wf-form4_142299772208656.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:42 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000038 · wf-form4_142265776706356.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,843 Underlying: Common Stock · 9,843 shares Expires 2016-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:42 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 27,248 | $70.97 | $1,933,790.56 |
DisclosureSEC source: 0000059478-15-000038 · wf-form4_142265776706356.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,403 Read SEC document |
| September 08, 2014 Filed Sep 10, 2014 18:32 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/05 (right to buy) · Derivative | 1,509 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-14-000151 · wf-form4_141037391764049.xml · derivative · entry 4 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,509 shares Expires 2015-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2014 Filed Sep 10, 2014 18:32 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,353 | $64.72 | $87,566.16 |
DisclosureSEC source: 0000059478-14-000151 · wf-form4_141037391764049.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,240 Read SEC document |
| September 08, 2014 Filed Sep 10, 2014 18:32 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 1,509 | $55.65 | $83,975.85 |
DisclosureSEC source: 0000059478-14-000151 · wf-form4_141037391764049.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2014 Filed Jan 29, 2015 18:33 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000013 · wf-form5_142255639647288.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,155 Read SEC document |
| February 03, 2014 Filed Feb 4, 2014 20:48 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,086 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-14-000073 · wf-form4_139154689662444.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,084 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2013. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.89 to $53.90. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 12,591 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000032 · wf-form4_139113183927494.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,591 Underlying: Common Stock · 12,591 shares Expires 2015-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:30 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 10,342 | $54.23 | $560,846.66 |
DisclosureSEC source: 0000059478-14-000032 · wf-form4_139113183927494.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,170 Read SEC document |
| October 21, 2013 Filed Jan 31, 2014 15:47 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 21 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000046 · wf-form5_139118322088549.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,828 Read SEC document |
| May 29, 2013 Filed Jan 31, 2014 15:47 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 92 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000046 · wf-form5_139118322088549.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,849 Read SEC document |
| February 08, 2013 Filed Feb 11, 2013 20:59 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,000 | $53.91 | $161,730.00 |
DisclosureSEC source: 0001209191-13-007676 · doc4.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,941 Read SEC document |
| January 25, 2013 Filed Jan 29, 2013 21:53 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 11,174 | $53.21 | $594,568.54 |
DisclosureSEC source: 0001209191-13-004998 · doc4.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,941 Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 2,748 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-055856 · doc4.xml · derivative · entry 4 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,748 shares Expires 2012-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 865 | $49.04 | $42,419.60 |
DisclosureSEC source: 0001209191-12-055856 · doc4.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,767 Read SEC document |
| December 03, 2012 Filed Dec 5, 2012 18:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 2,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-055856 · doc4.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 22:48 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6,948 | $39.44 | $274,029.12 |
DisclosureSEC source: 0001209191-12-006151 · doc4.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,884 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.